Physician profile
Gregory W Schmidt
NPI 1740326081
$4,659.99
in general payments reported to CMS, 2019-2025
22 companies · $3,370 in 2025
The $3,370 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.03 · 2021: $143 · 2022: $13.31 · 2023: $541 · 2024: $573 · 2025: $3,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,646 · Long Term Medical Supply Or Device Loan: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,645.93 |
| Long Term Medical Supply Or Device Loan | $838.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,831.84 | 2021-2025 | Unity, Clareon, Clareon Panoptix Pro |
| Sight Sciences, INC. | $494.28 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Leo Pharma INC. | $407.57 | 2023-2025 | Adbry, Anzupgo |
| Bausch & Lomb Americas INC. | $338.09 | 2025 | Envista Envy Iol, Miebo |
| Abbvie INC. | $228.32 | 2023-2025 | Alphagan P, Vuity, Lumigan |
| Lilly USA, LLC | $194.58 | 2025 | Ebglyss, Taltz |
| Glaukos Corporation | $185.78 | 2024 | Idose |
| Astrazeneca Pharmaceuticals LP | $183.25 | 2023-2025 | Tezspire |
| Csl Behring | $172.73 | 2025 | Andembry, Hizentra |
| Johnson & Johnson Surgical Vision, INC. | $140.07 | 2023 | Catalys System |
| Kedrion Biopharma, INC. | $124.96 | 2025 | Coagadex |
| Biocryst US Sales Co., LLC | $58.20 | 2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $55.31 | 2025 | Sajazir |
| Tarsus Pharmaceuticals, INC. | $44.49 | 2025 | Xdemvy |
| Genzyme Corporation | $44.26 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $33.34 | 2019-2022 | |
| Pharming Healthcare, INC. | $28.45 | 2025 | Ruconest |
| Blueprint Medicines Corporation | $23.41 | 2024 | Ayvakit |
| Horizon Therapeutics Plc | $22.75 | 2023 | Tepezza |
| Amgen INC. | $21.37 | 2025 | Tepezza |
| Glaxosmithkline, LLC. | $13.61 | 2025 | Arexvy, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $13.33 | 2024 | Takhzyro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.